Senseonics (SENS) Stock
Long term implantable glucose monitoring provider for diabetics. Here's the price, business snapshot, and what's worth knowing about Senseonics in October 2026.
Senseonics Holdings, Inc. (SENS) develops and commercialises the Eversense family of long‑term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s differentiated technology focuses on an implanted sensor that can remain under the skin for months, combined with a removable transmitter and mobile app to deliver glucose readings and alerts. Revenue comes mainly from sales of sensors, transmitters, and related services, though the business can be sensitive to reimbursement, clinical adoption and distribution partnerships. With a market cap of about $310.8M, Senseonics operates in a competitive market that includes non‑implantable CGM leaders and emerging entrants. Key investor considerations include clinical performance, regulatory milestones, payer coverage, and the company’s cash position because medical device growth often requires sustained investment. This summary is educational only and not personal financial advice; values can fall as well as rise and prospective investors should do their own research or speak to a qualified adviser.
Senseonics (SENS) Stock Forecast
Analyst price target, next 12 months
$11.60
+17.4% vs today's $9.88
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Senseonics have a consensus 12-month target of $11.60, above the current price of $9.88.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping SENSEONICS stock as it has room to grow, but not aggressively.
Financial Health
Senseonics is generating good revenue and cash flow, with a solid profit margin, indicating healthy operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Long‑life CGM thesis
Eversense’s multi‑month implantable sensor targets convenience and adherence advantages versus short‑term sensors, though clinical acceptance and payer reimbursement remain crucial.
Diabetes market scale
The global diabetes population creates significant demand for monitoring solutions; market growth could support niche players, but larger incumbents intensify competition.
Regulatory and adoption
Regulatory approvals and distribution partnerships drive uptake, while capital needs and device performance can cause share price volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
